SUNSHINE PHARMA (06887) Income Statement & Earnings

42.360
-0.300-0.70%

Market Closed May 8 16:00 CST

24.40BMarket Cap80.84P/E (TTM)

SUNSHINE PHARMA (06887) Income Statement

All

YOY

Hide blank lines

(FY)Dec 31, 2025

(Q6)Jun 30, 2025

(FY)Dec 31, 2024

(Q6)Jun 30, 2024

(FY)Dec 31, 2023

(Q6)Jun 30, 2023

(FY)Dec 31, 2022

(FY)Dec 31, 2021

Turnover

19.81%4.82B

-24.95%1.94B

-37.06%4.02B

-20.72%2.58B

67.44%6.39B

--3.26B

260.40%3.81B

--1.06B

Operating income

19.81%4.82B

-24.95%1.94B

-37.06%4.02B

-20.72%2.58B

67.44%6.39B

3.26B

260.40%3.81B

1.06B

Cost of sales

-17.64%-1.13B

12.97%-470.06M

26.62%-960.27M

17.06%-540.13M

-46.80%-1.31B

---651.26M

-86.93%-891.38M

---476.86M

Operating expenses

-17.64%-1.13B

12.97%-470.06M

26.62%-960.27M

17.06%-540.13M

-46.80%-1.31B

-651.26M

-86.93%-891.38M

-476.86M

Gross profit

20.49%3.69B

-28.12%1.47B

-39.76%3.06B

-21.64%2.04B

73.74%5.08B

2.61B

402.71%2.92B

581.29M

Selling expenses

-60.19%-1.92B

-4.66%-715.62M

24.10%-1.2B

10.77%-683.74M

-26.76%-1.58B

---766.26M

-126.31%-1.24B

---549.77M

Administrative expenses

-17.35%-653.79M

-11.19%-309.06M

-15.89%-557.12M

-35.37%-277.96M

-23.94%-480.72M

---205.33M

1.46%-387.87M

---393.62M

Research and development expenses

26.92%-648.69M

13.46%-348.22M

-7.28%-887.65M

8.15%-402.38M

-4.52%-827.42M

---438.08M

28.02%-791.64M

---1.1B

Impairment and provision

157.63%72.62M

531.27%80.35M

-3,992.59%-126.01M

-1,146.69%-18.63M

-219.57%-3.08M

--1.78M

141.73%2.58M

---6.17M

-Other impairment is provision

157.63%72.62M

531.27%80.35M

-3,992.59%-126.01M

-1,146.69%-18.63M

-219.57%-3.08M

--1.78M

141.73%2.58M

---6.17M

Special items of operating profit

46.73%131.68M

-55.59%34.83M

121.23%89.74M

180.34%78.44M

67.34%-422.67M

---97.63M

-576.97%-1.29B

--271.3M

Operating profit

75.99%669.72M

-71.54%209.9M

-78.45%380.55M

-32.95%737.54M

322.73%1.77B

1.1B

33.74%-792.94M

-1.2B

Financing cost

4.00%-230.2M

11.95%-114.29M

37.00%-239.79M

39.79%-129.81M

44.59%-380.59M

---215.59M

24.66%-686.88M

---911.77M

Share of profits of associates

-83.28%49K

406.25%49K

1,110.34%293K

---16K

---29K

----

Earning before tax

211.63%439.56M

-84.26%95.65M

-89.82%141.05M

-31.29%607.72M

193.62%1.39B

884.44M

29.82%-1.48B

-2.11B

Tax

-45.83%-169.53M

39.68%-81M

68.71%-116.25M

58.64%-134.29M

-681.44%-371.58M

---324.72M

1.80%63.91M

--62.78M

After-tax profit from continuing operations

988.72%270.03M

-96.91%14.65M

-97.55%24.8M

-15.42%473.43M

171.61%1.01B

559.72M

30.79%-1.42B

-2.05B

Earning after tax

988.72%270.03M

-96.91%14.65M

-97.55%24.8M

-15.42%473.43M

171.61%1.01B

559.72M

30.79%-1.42B

-2.05B

Minority profit

-101.04%-2.41M

-81.58%61.02M

-71.98%232.24M

-32.71%331.28M

501.02%828.95M

--492.35M

29.83%-206.71M

---294.6M

Profit attributable to shareholders

231.34%272.44M

-132.62%-46.37M

-212.17%-207.43M

110.99%142.14M

115.29%184.92M

67.37M

30.95%-1.21B

-1.75B

Basic earnings per share

219.15%0.56

-134.38%-0.11

-206.82%-0.47

88.24%0.32

113.37%0.44

0.17

30.59%-3.29

-4.74

Diluted earnings per share

217.02%0.55

-134.38%-0.11

-206.82%-0.47

88.24%0.32

113.37%0.44

0.17

30.59%-3.29

-4.74

Currency Unit

CNY

Accounting Standards

IAS

Audit Opinions

Unqualified Opinion

Auditor

KPMG

	(FY)Dec 31, 2025	(Q6)Jun 30, 2025	(FY)Dec 31, 2024	(Q6)Jun 30, 2024	(FY)Dec 31, 2023	(Q6)Jun 30, 2023	(FY)Dec 31, 2022	(FY)Dec 31, 2021
Turnover	19.81%4.82B	-24.95%1.94B	-37.06%4.02B	-20.72%2.58B	67.44%6.39B	--3.26B	260.40%3.81B	--1.06B
Operating income	19.81%4.82B	-24.95%1.94B	-37.06%4.02B	-20.72%2.58B	67.44%6.39B	3.26B	260.40%3.81B	1.06B
Cost of sales	-17.64%-1.13B	12.97%-470.06M	26.62%-960.27M	17.06%-540.13M	-46.80%-1.31B	---651.26M	-86.93%-891.38M	---476.86M
Operating expenses	-17.64%-1.13B	12.97%-470.06M	26.62%-960.27M	17.06%-540.13M	-46.80%-1.31B	-651.26M	-86.93%-891.38M	-476.86M
Gross profit	20.49%3.69B	-28.12%1.47B	-39.76%3.06B	-21.64%2.04B	73.74%5.08B	2.61B	402.71%2.92B	581.29M
Selling expenses	-60.19%-1.92B	-4.66%-715.62M	24.10%-1.2B	10.77%-683.74M	-26.76%-1.58B	---766.26M	-126.31%-1.24B	---549.77M
Administrative expenses	-17.35%-653.79M	-11.19%-309.06M	-15.89%-557.12M	-35.37%-277.96M	-23.94%-480.72M	---205.33M	1.46%-387.87M	---393.62M
Research and development expenses	26.92%-648.69M	13.46%-348.22M	-7.28%-887.65M	8.15%-402.38M	-4.52%-827.42M	---438.08M	28.02%-791.64M	---1.1B
Impairment and provision	157.63%72.62M	531.27%80.35M	-3,992.59%-126.01M	-1,146.69%-18.63M	-219.57%-3.08M	--1.78M	141.73%2.58M	---6.17M
-Other impairment is provision	157.63%72.62M	531.27%80.35M	-3,992.59%-126.01M	-1,146.69%-18.63M	-219.57%-3.08M	--1.78M	141.73%2.58M	---6.17M
Special items of operating profit	46.73%131.68M	-55.59%34.83M	121.23%89.74M	180.34%78.44M	67.34%-422.67M	---97.63M	-576.97%-1.29B	--271.3M
Operating profit	75.99%669.72M	-71.54%209.9M	-78.45%380.55M	-32.95%737.54M	322.73%1.77B	1.1B	33.74%-792.94M	-1.2B
Financing cost	4.00%-230.2M	11.95%-114.29M	37.00%-239.79M	39.79%-129.81M	44.59%-380.59M	---215.59M	24.66%-686.88M	---911.77M
Share of profits of associates	-83.28%49K	406.25%49K	1,110.34%293K	---16K	---29K	----	----	----
Earning before tax	211.63%439.56M	-84.26%95.65M	-89.82%141.05M	-31.29%607.72M	193.62%1.39B	884.44M	29.82%-1.48B	-2.11B
Tax	-45.83%-169.53M	39.68%-81M	68.71%-116.25M	58.64%-134.29M	-681.44%-371.58M	---324.72M	1.80%63.91M	--62.78M
After-tax profit from continuing operations	988.72%270.03M	-96.91%14.65M	-97.55%24.8M	-15.42%473.43M	171.61%1.01B	559.72M	30.79%-1.42B	-2.05B
Earning after tax	988.72%270.03M	-96.91%14.65M	-97.55%24.8M	-15.42%473.43M	171.61%1.01B	559.72M	30.79%-1.42B	-2.05B
Minority profit	-101.04%-2.41M	-81.58%61.02M	-71.98%232.24M	-32.71%331.28M	501.02%828.95M	--492.35M	29.83%-206.71M	---294.6M
Profit attributable to shareholders	231.34%272.44M	-132.62%-46.37M	-212.17%-207.43M	110.99%142.14M	115.29%184.92M	67.37M	30.95%-1.21B	-1.75B
Basic earnings per share	219.15%0.56	-134.38%-0.11	-206.82%-0.47	88.24%0.32	113.37%0.44	0.17	30.59%-3.29	-4.74
Diluted earnings per share	217.02%0.55	-134.38%-0.11	-206.82%-0.47	88.24%0.32	113.37%0.44	0.17	30.59%-3.29	-4.74
Currency Unit	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY
Accounting Standards	IAS	IAS	IAS	IAS	IAS	IAS	IAS	IAS
Audit Opinions	Unqualified Opinion	--	Unqualified Opinion	--	Unqualified Opinion	--	Unqualified Opinion	Unqualified Opinion
Auditor	KPMG	--	KPMG	--	KPMG	--	KPMG	KPMG

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome Show More

牛牛課堂

Oct 13, 2025 18:05

[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?

Food流油

Apr 14, 2025 15:43

"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"